Published in final edited form as:

Bioorg Med Chem Lett. 2011 May 15; 21(10): 3099–3102. doi:10.1016/j.bmcl.2011.03.019.

Cyclic Lactam Hybrid α -MSH/Agouti-Related Protein (AGRP) Analogues with Nanomolar Range Binding Affinities at the Human Melanocortin Receptors

Alexander V. Mayorov^b, Minying Cai^a, Erin S. Palmer^a, Dustin K. Tanaka^a, James P. Cain^a, Matthew M. Dedek^a, Bahar Tan^a, Dev Trivedi^a, and Victor J. Hruby^{a,*}

^aDepartment of Chemistry, University of Arizona, Tucson, Arizona 85721, USA

Abstract

A novel hybrid melanocortin pharmacophore was designed based on the topographical similarities between the pharmacophores of Agouti related protein (AGRP) an endogenous melanocortin antagonist, and α -melanocyte-stimulating hormone (α -MSH), an endogenous melanocortin agonist. When employed in two different 23-membered macrocyclic lactam peptide templates, the designed hybrid AGRP/MSH pharmacophore yielded non-competitive ligands with nanomolar range binding affinities. The topography-based pharmacophore hybridization strategy will prove useful in development of unique non-competitive melanocortin receptor modulators.

Keywords

α -MSH; Agouti-related protein; human melanocortin receptors; hybrid pharmacophore; macrocyclic peptide

Proopiomelanocortin (POMC) is a primordial gene found in virtually all vertebrates. The peptide hormones and neurotransmitters derived from POMC by post-translational processing, including α -, β -, and γ -melanocyte stimulating hormones (MSHs) and adrenocorticotropin (ACTH),¹ (Figure 1) as well as their targets, the melanocortin receptors (MCRs), are responsible for many physiological functions critical for survival.^{2,3} These functions include regulation of feeding behavior and energy homeostasis,^{3–5} control of the immune system and inflammation,^{1,2} skin pigmentation,^{1,2} cardiovascular function,⁶ sexual function and procreation,^{4,7,8} modulation of aggressive/defensive behavior,⁹ thermoregulation,¹⁰ and mediation of pain.^{11,12} The multitude of biological functions displayed by the melanocortin receptors and their ligands offer attractive opportunities in addressing a variety of medical conditions including obesity,⁴ cachexia,¹³ inflammatory disorders,^{14,15} sexual dysfunction,^{4,16} and even infectious diseases.¹⁷

Significant efforts have been made in development of more potent and selective melanocortin ligands based on the endogenous agonists α -, β -, and γ -MSH,^{18–21} while structure-activity relationship studies on the endogenous antagonists Agouti-signaling (ASIP)²² and Agouti-related (AGRP)²³ proteins (Figure 1) have received comparatively less

*To whom correspondence should be addressed. Phone: (520) 621-6332. Fax: (520) 621-8407. hruby@u.arizona.edu.

^bCurrent address: Henry M. Jackson Foundation for Advancement of Military Medicine, Rockville, Maryland 20850, USA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

attention.²⁴ The Agouti (-Arg-Phe-Phe-) tripeptide pharmacophore²⁵ differs significantly from the MSH (-His-Phe-Arg-Trp-) tetrapeptide pharmacophore,²⁶ and is a part of the central loop within the inhibitor cystine knot (ICK) motif in both Agouti proteins,²⁷ which suggests that the SAR trends observed for MSH peptides are unlikely to be manifested in the Agouti protein-derived analogues (Figure 1). Previous literature reports describe truncation of both ASIP and AGRP sequences resulting in substantial loss of both binding affinities and antagonist/inverse agonist potencies,^{28, 29} while the Ac-mini-AGRP(87–120, C105A)-NH₂ variant has been reported to be equipotent to the full-length AGRP,³⁰ which points to possible significance of *N*- and *C*-terminal sequences of these proteins in receptor-ligand interactions. When the His-*D*-Phe-Arg-Trp MSH tetrapeptide pharmacophore was used to replace the Arg-Phe-Phe tripeptide sequence, the resulting cyclic peptide was a relatively potent agonist,^{31, 32} which can be attributed to the well-known propensity of the His-*D*-Phe-Arg-Trp tetrapeptide sequence to inducing melanocortin agonist activity in a wide variety of linear and cyclic peptide templates.^{19,20,26,33–36} In another instance, replacement of the MSH pharmacophoric *D*-Phe-Arg-Trp tripeptide sequence with the agouti Arg-Phe-Phe sequence in the linear and cyclic α -MSH templates produced nanomolar range mMC1R agonists, which however registered >300 fold lower than the agonist potency of the super-agonist MT-II control as determined by CRE/ β -galactosidase assay.³⁷ Our recent report³⁸ described a novel MSH/ASIP hybrid pharmacophore Arg-*L/D*-Phe-Xaa-*L/D*-Trp (Xaa = Cys or Glu), which, when incorporated into a monomeric cyclic disulfide template, yielded peptides with hMC3R-selective non-competitive binding affinities. In contrast, in a cyclodimeric lactam template this pharmacophore produced nanomolar range (25–120 nM) hMC1R-selective full and partial agonists.

Comparison of the NMR structures of AGRP (110–117)²⁷ and MT-II³⁹ revealed striking similarities. Both structures feature a β -turn-like motif within the pharmacophore region, which spans over the first two residues in the His-*D*-Phe-Arg-Trp MSH pharmacophore, and the over the last two residues of the Arg-Phe-Phe-Asn AGRP pharmacophore. Intriguingly, a superposition of these pharmacophoric sequences in a retro-directed fashion (*i.e.*, the C $^{\alpha}$ atoms of His⁶, *D*-Phe⁷, and Arg⁸ residues of MT-II overlapped with the C $^{\alpha}$ atoms of the Asn¹¹⁴, Phe¹¹³, and Phe¹¹² residue of AGRP, respectively) revealed fairly similar overall topographies, matching the loci of the three pharmacophoric elements (two aromatic side chains, and a positively charged Arg side chain) that are believed to be involved in receptor-ligand interactions of both α -MSH analogues and AGRP (Figure 2). The positions of Trp⁹ (MT-II) and Arg¹¹¹ (AGRP) showed significant deviation, which was deemed unsubstantial, as much structural flexibility around Trp⁹ in MSH analogues is known to be well tolerated by the hMCRs.⁴⁰ The hypothesis that the pharmacophores of α -MSH-derived ligands and AGRP are retro-directed in relation to one another suggests that a hybrid pharmacophore can be obtained by a) replacement of Phe¹¹² with Trp; b) *D*-amino acid substitutions in Phe¹¹³ and Asn¹¹⁴ positions to stabilize the β -turn motif; c) Asn¹¹⁴ position substitutions with other amino acids, in a fashion similar to His⁶ position substitutions in α -MSH analogues; specifically, N114Q, N114H and N114R substitutions were planned, since similar modifications were reported previously for MSH-derived templates to affect the potency and receptor selectivity of the resulting peptide analogues (Figure 3).^{41,42} The resulting pharmacophore sequences were incorporated into two different 23-membered macrocyclic lactam templates, which provide global constraints (Table 1).^{43–45}

The binding affinities and the agonist activities of the cyclic α -MSH analogues at the hMC1, 3, 4 and 5R are summarized in Table 1.^{46–50} Analogues **1–5**, employing the Ac-c[Asp-Arg-Trp-Xaa-Yaa-Lys]-NH₂ template (Xaa = Phe, Nal(2'); Yaa = *D*-Asn, *D*-Gln, *D*-Arg) exhibited no binding affinity and no cAMP stimulation at 10 μ M at any of the melanocortin receptors which suggested that restricting the hybrid pharmacophore to the

first four amino acids of the AGRP pharmacophore sequence Arg¹¹¹-Phe¹¹²-Phe¹¹³-Asn¹¹⁴-Ala¹¹⁵-Phe¹¹⁶ may be insufficient to induce receptor recognition in the antagonist series.

The second cyclic lactam template c[Arg-Trp-Xaa-Yaa-Ala-Phe-Glu]-NH₂ (Xaa = Phe, Nal(2'), *D*-Phe; Yaa = Asn, Arg, His, *D*-Asn, *D*-Gln, *D*-Arg, *D*-His) was constructed to include all six of these amino acids, while maintaining the same macrocycle size. Analogues **6–9**, possessing Phe¹¹³/Nal(2')¹¹³-*D*-Asn¹¹⁴/*D*-Gln¹¹⁴ modifications, showed no improvement over the first template and had no binding affinity and no cAMP stimulation at 10 μM. Since binding affinities and agonist potencies of α-MSH-derived peptides generally benefit from polar basic amino acids in the position 6, the Asn¹¹⁴ residue in the hybrid peptide template was replaced with *D*-His and *D*-Arg to yield analogues **10** and **11**, respectively. Analogue **10** exhibited a weak binding affinity at the hMC1R (IC₅₀ > 4 μM) at about 40% binding efficiency (maximal % displacement of [¹²⁵I]-NDP-α-MSH). The beneficial influence of basic amino acid substitution at position 114 was further confirmed with analogue **11**, which was found to have a nanomolar range binding affinity at the hMC3R (IC₅₀ = 500 nM), albeit with only 30% binding efficiency, as well as weaker binding affinities at the hMC1R (IC₅₀ > 4 μM) and the hMC5R (IC₅₀ > 1 μM). The all-*L* Asn¹¹⁴-analogue **12**, *D*-Phe¹¹³, Asn¹¹⁴-analogue **13** and *D*-Phe¹¹³, His¹¹⁴-analogue **14** were devoid of any binding affinity or agonist activity at 10 μM. In contrast, the *D*-Phe¹¹³, Arg¹¹⁴-analogue **15** was determined to be a nanomolar partial agonist at the hMC1R (EC₅₀ = 26 nM, 30% maximal cAMP) with a weak binding affinity (IC₅₀ > 1 μM, 65% binding efficiency), and with nanomolar binding affinity at the hMC3R (IC₅₀ = 400 nM, 80% binding efficiency), the hMC4R (IC₅₀ = 515 nM, 40% binding efficiency), the hMC5R (IC₅₀ = 300 nM, 75% binding efficiency). This result is consistent with our earlier reports, which linked the augmented binding affinity and agonist potency with increased charge⁴², although comparison with analogue **11** may suggest that *D*-amino acid substitution at position 113 may be needed for a suitable secondary structure of the hybrid pharmacophore for favorable receptor-ligand interactions.

In summary, a hybrid AGRP/MSH pharmacophore was designed on the basis of the hypothesis that the pharmacophores of α-MSH-derived ligands and AGRP are retro-directed in relation to one another. The resulting hybrid pharmacophore was explored in two macrocyclic lactam templates. Asn¹¹⁴ → Arg¹¹⁴ substitutions with a simultaneous *D*-amino acid substitutions yielded analogues with high nanomolar range binding affinities at the hMC3-5R and nanomolar range partial agonist activity at the hMC1R, such as analogue **15**, c[Arg-Trp-*D*-Phe-Arg-Ala-Phe-Glu]-NH₂. These new peptide analogues will aid in elucidation of the mechanism of non-competitive hMCR antagonism and GPCR modulation.

Acknowledgments

This work was supported by grants from the U.S. Public Health Service, National Institutes of Health DK-17420 and DA-06284. The opinions expressed are those of the authors and not necessarily those of the USPHS.

References and notes

1. Hadley, ME., editor. The Melanotropic Peptides. CRC Press; Boca Raton, Florida: 1988.
2. Cone, RD., editor. The Melanocortin Receptors. Humana Press; Totowa, New Jersey: 2000.
3. Cone RD. Endocrine Rev. 2006; 27:736. [PubMed: 17077189]
4. Wikberg JES, Mutulis F. Nature Rev Drug Disc. 2008; 7:307.
5. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Nature. 1997; 385:165. [PubMed: 8990120]
6. Ni XP, Butler AA, Cone RD, Humphreys MH. J Hypertension. 2006; 24:2239.

7. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. *J Urology*. 1998; 160:389.
8. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah T, Wessells H. *Curr Topics Med Chem*. 2007; 7:1098.
9. Morgan C, Thomas RE, Cone RD. *Horm Behav*. 2004; 45:58. [PubMed: 14733892]
10. Chen WB, Kelly MA, Opitz Araya X, Thomas RE, Low MJ, Cone RD. *Cell*. 1997; 91:789. [PubMed: 9413988]
11. Mogil JS, Wilson SG, Chesler EJ, Rankin AL, Nemmani KVS, Lariviere WR, Groce MK, Wallace MR, Kaplan L, Staud R, Ness TJ, Glover TL, Stankova M, Mayorov A, Hruby VJ, Grisell JE, Fillingim RB. *Proc Nat Acad Sci USA*. 2003; 100:4867. [PubMed: 12663858]
12. Vrinten DH, Kalkman CJ, Adan RAH, Gispen WH. *Eur J Pharmacol*. 2001; 429:61. [PubMed: 11698027]
13. Yang YK, Harmon CM. *Obesity Rev*. 2003; 4:239.
14. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. *Endocr Rev*. 2008; 29:581. [PubMed: 18612139]
15. Yoon SW, Goh SH, Chun JS, Cho EW, Lee MK, Kim KL, Kim JJ, Kim CJ, Poo H. *J Biol Chem*. 2003; 278:32914. [PubMed: 12816950]
16. Brown AD, Blagg J, Reynolds DS. *Drug Discovery Today*. 2007; 12:757. [PubMed: 17826689]
17. Charnley M, Moir AJG, Douglas CWI, Haycock JW. *Peptides*. 2008; 29:1004. [PubMed: 18355945]
18. Hruby VJ, Cai M, Grieco P, Han G, Kavarana M, Trivedi D. *Ann NY Acad Sci*. 2003; 994:12. [PubMed: 12851293]
19. Holder JR, Haskell-Luevano C. *Med Res Rev*. 2004; 24:325. [PubMed: 14994367]
20. Cai M, Mayorov AV, Ying J, Stankova M, Trivedi D, Cabello C, Hruby VJ. *Peptides*. 2005; 26:1481. [PubMed: 15876475]
21. Hruby VJ, Cai M, Cain JP, Mayorov AV, Dedek M, Trivedi D. *Curr Topics Med Chem*. 2007; 7:1107.
22. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD. *Nature*. 1994; 371:799. [PubMed: 7935841]
23. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. *Science*. 1997; 278:135. [PubMed: 9311920]
24. Wilczynski AM, Joseph CG, Haskell-Luevano C. *Med Res Rev*. 2005; 25:545. [PubMed: 16044415]
25. Kiefer LL, Veal JM, Mountjoy KG, Wilkison WO. *Biochemistry*. 1998; 37:991. [PubMed: 9454589]
26. Hruby VJ, Wilkes BC, Hadley ME, Al-Obeidi F, Sawyer TK, Staples DJ, DeVaux AE, Dym O, Castrucci AMdL. *J Med Chem*. 1987; 30:2126. [PubMed: 2822931]
27. McNulty JC, Thompson DA, Bolin KA, Wilken J, Barsh GS, Millhauser GL. *Biochemistry*. 2001; 40:15520. [PubMed: 11747427]
28. Tota MR, Smith TS, Mao C, MacNeil T, Mosley RT, Van der Ploeg LHT, Fong TM. *Biochemistry*. 1999; 38:897. [PubMed: 9893984]
29. Joseph CG, Bauzo RM, Xiang Z, Shaw AM, Millard WJ, Haskell-Luevano C. *Peptides*. 2003; 24:263. [PubMed: 12668211]
30. Jackson PJ, McNulty JC, Yang YK, Thompson DA, Chai B, Gantz I, Barsh GS, Millhauser GL. *Biochemistry*. 2002; 41:7565. [PubMed: 12056887]
31. Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, Sorensen NB, Shaw AM, Millard WJ, Richards NG, Haskell-Luevano C. *J Med Chem*. 2004; 47:2194. [PubMed: 15084118]
32. Jackson PJ, Yu B, Hunrichs B, Thompson DA, Chai B, Gantz I, Millhauser GL. *Peptides*. 2005; 26:1978. [PubMed: 16009463]
33. Fung S, Hruby VJ. *Curr Opin Chem Biol*. 2005; 9:352.
34. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. *Proc Natl Acad Sci USA*. 1980; 77:5754. [PubMed: 6777774]

35. Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. *J Am Chem Soc.* 1989; 111:3413.
36. Hruby VJ, Lu D, Sharma SD, Castrucci AdeL, Kesterson RA, Al-Obeidi FA, Hadley ME, Cone RD. *J Med Chem.* 1995; 38:3454. [PubMed: 7658432]
37. Joseph CG, Wilczynski A, Holder JR, Xiang Z, Bauzo RM, Scott JW, Haskell-Luevano C. *Peptides.* 2003; 24:1899. [PubMed: 15127941]
38. Mayorov AV, Cai M, Palmer ES, Liu Z, Cain JP, Vagner J, Trivedi D, Hruby VJ. *Peptides.* 2010; 31:1894. [PubMed: 20688117]
39. Ying J, Kövér KE, Gu X, Han G, Trivedi DB, Kavarana MJ, Hruby VJ. *Biopolymers (Peptide Science).* 2003; 71:696. [PubMed: 14991679]
40. Cai M, Mayorov AV, Cabello C, Stankova M, Trivedi D, Hruby VJ. *J Med Chem.* 2005; 48:1839. [PubMed: 15771429]
41. Nijenhuis WAJ, Kruijtz JAW, Wanders N, Vrinten DH, Garner KM, Schaaper WMM, Meloen RH, Gispén WH, Liskamp RM, Adan RAH. *Peptides.* 2003; 24:271. [PubMed: 12668212]
42. Mayorov AV, Cai M, Chandler KB, Petrov RR, Van Scoy AR, Yu Z, Tanaka DK, Trivedi D, Hruby VJ. *J Med Chem.* 2006; 49:1946. [PubMed: 16539382]
43. All peptides in this study were synthesized manually by the *N*^α-Fmoc solid-phase methodology on Rink amide AM resin using DIC and Cl-HOBt as the coupling reagents, purified and characterized by chromatographic methods, HR-MS and ¹H NMR, as described in previous reports.^{42,44,45}
44. Ballet S, Mayorov AV, Cai M, Tymecka D, Chandler KB, Palmer ES, Rompaey KV, Misicka A, Tourwé D, Hruby VJ. *Bioorg Med Chem Lett.* 2007; 17:2492. [PubMed: 17314042]
45. Qu H, Cai M, Mayorov AV, Grieco P, Zingsheim M, Trivedi D, Hruby VJ. *J Med Chem.* 2009; 52:3627. [PubMed: 19473029]
46. Competition binding experiments^{42,45} were carried out using whole HEK293 cells stably expressing human MC1, MC3, MC4, and MC5 receptors. HEK293 cells transfected with hMCRs^{47–49} were seeded on 96-well plates 48 h before assay (50,000 cells/well). For the assay, the cell culture medium was aspirated and the cells were washed once with a freshly prepared MEM buffer containing 100% minimum essential medium with Earle's salt (MEM, Gibco) and 25 mM sodium bicarbonate. Next, the cells were incubated for 40 min at 37 °C with different concentrations of unlabeled peptide and labeled [¹²⁵I]-[Nle⁴, D-Phe⁷]-α-MSH (Perkin-Elmer Life Science, 20,000 cpm/well, 33.06 pM) diluted in a 125 μL of freshly prepared binding buffer containing 100% MEM, 25 mM Hepes (pH 7.4), 0.2% bovine serum albumin, 1 mM 1,10-phenanthroline, 0.5 mg/L leupeptin, 200 mg/L bacitracin. The assay medium was subsequently removed, the cells were washed once with basic medium, and then lysed by the addition of 100 μL of 0.1 M NaOH and 100 μL of 1% Triton X-100. The lysed cells were transferred to 12 × 75 mm borosilicate glass tubes, and the radioactivity was measured by a Wallac 1470 WIZARD Gamma Counter.
47. Cai M, Cai C, Mayorov AV, Xiong C, Cabello CM, Soloshonok VA, Swift JR, Trivedi D, Hruby VJ. *J Pept Res.* 2004; 63:116. [PubMed: 15009533]
48. Haskell-Luevano C, Miwa H, Dickinson C, Hruby VJ, Yamada T, Gantz I. *Biochem Biophys Res Commun.* 1994; 204:1137. [PubMed: 7980588]
49. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, Delvalle J, Yamada T. *J Biol Chem.* 1993; 268:15174. [PubMed: 8392067]
50. Adenylate Cyclase assay: HEK 293 cells transfected with human melanocortin receptors⁴⁷ were grown to confluence in MEM (Gibco) containing 10% fetal bovine serum, 100 units/mL penicillin and streptomycin, and 1 mM sodium pyruvate. The cells were seeded on 96-well plates 48 h before assay (50,000 cells/well). For the assay, the cell culture medium was removed and the cells were rinsed with 100 μL MEM buffer (Gibco). An aliquot (100 μL) of the Earle's balanced salt solution with 5 mM isobutylmethylxanthine (IBMX) was placed in each well along for 1 min at 37 °C. Next, aliquots (25 μL) of melanotropin peptides of varying concentrations were added, and the cells were incubated for 3 min at 37 °C. The reaction was stopped by aspirating the assay buffer and adding 60 μL ice-cold Tris/EDTA buffer to each well, then placing the plates in a boiling water bath for 7 min. The cell lysates were then centrifuged for 10 min at 2300g. A 50 μL aliquot of the supernatant was transferred to another 96-well plate and placed with 50 μL [³H]cAMP and 100 μL protein kinase A (PKA) buffer in an ice bath for 2–3 h. The PKA-buffer consisted of Tris/EDTA-buffer with 60 μg/mL PKA and 0.1% bovine serum albumin by weight. The incubation

mixture was filtered through 1.0 μ m glass fiber filters in MultiScreenTM-FB 96-well plates (Millipore, Billerica, MA). The total [³H]cAMP was measured by a Wallac MicroBeta TriLux 1450 LSC and Luminescence Counter (Perkin-Elmer Life Science, Boston, MA). The cAMP accumulation data for each peptide analogue were determined with the help of a cAMP standard curve generated by the same method as described above. IC₅₀ and EC₅₀ values represent the mean of two experiments performed in triplicate. IC₅₀ and EC₅₀ estimates and their associated standard errors were determined by fitting the data using a nonlinear least squares analysis, with the help of GraphPad Prism 4 (GraphPad Software, San Diego, CA).

Figure 1.
Sequences of some endogenous and synthetic melanotropin peptides.

Figure 2.

Stereo view of the retro-directed superposition of NMR structures of the pharmacophoric tetrapeptide sequences of endogenous hMC3/4R antagonist AGRP (blue) and of non-selective super agonist MT-II (red) (rmsd = 0.17 Å, C $^{\alpha}$ atoms of His⁶, D-Phe⁷, and Arg⁸ residues of MT-II overlapped with the C $^{\alpha}$ atoms of the Asn¹¹⁴, Phe¹¹³, and Phe¹¹² residue of AGRP, respectively). Hydrogens are omitted for clarity.

Figure 3.
Design of the hybrid α -MSH/Agouti-related protein (AGRP) pharmacophore.

Table 1

Binding Affinities and cAMP Activities of cyclic α -MSH/AGRP Hybrid Analogues at hMCRs ^a

No.	Sequence	hMC1R				hMC3R				hMC4R				hMC5R			
		IC ₅₀ (nM)	% BE	EC ₅₀ (nM)	Act %	IC ₅₀ (nM)	% BE	EC ₅₀ (nM)	Act %	IC ₅₀ (nM)	% BE	EC ₅₀ (nM)	Act %	IC ₅₀ (nM)	% BE	EC ₅₀ (nM)	Act %
1	Ac-c[Asp-Arg-Trp-Phe-D-Asn-Lys]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
2	Ac-c[Asp-Arg-Trp-Nal-D-Asn-Lys]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
3	Ac-c[Asp-Arg-Trp-Phe-D-Gln-Lys]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
4	Ac-c[Asp-Arg-Trp-Nal-D-Gln-Lys]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
5	Ac-c[Asp-Arg-Trp-Phe-D-Arg-Lys]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
6	c[Arg-Trp-Phe-D-Asn-Ala-Phe-Glu]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
7	c[Arg-Trp-Nal-D-Asn-Ala-Phe-Glu]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
8	c[Arg-Trp-Phe-D-Gln-Ala-Phe-Glu]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
9	c[Arg-Trp-Nal-D-Gln-Ala-Phe-Glu]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
10	c[Arg-Trp-Phe-D-His-Ala-Phe-Glu]-NH ₂	>4000	40	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
11	c[Arg-Trp-Phe-D-Arg-Ala-Phe-Glu]-NH ₂	>4000	80	NA	0	500±100	30	NA	0	NB	0	NA	0	NB	0	NA	0
12	c[Arg-Trp-Phe-Asn-Ala-Phe-Glu]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
13	c[Arg-Trp-D-Phe-Asn-Ala-Phe-Glu]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
14	c[Arg-Trp-D-Phe-His-Ala-Phe-Glu]-NH ₂	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0	NB	0	NA	0
15	c[Arg-Trp-D-Phe-Arg-Ala-Phe-Glu]-NH ₂	>1000	65	26±10	30	400±80	80	NA	0	515±40	40	NA	0	300±30	75	NA	0
MT-II	Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH ₂	2.3±0.9	100	1.02±0.4	100	8.0±1.3	100	5.1±0.3	100	2.3±0.85	100	2.1±0.6	100	4.2±1.3	100	5.7±2.2	100

^aIC₅₀ = concentration of peptide at 50% specific binding (N=4). % BE = maximal % of [¹²⁵I]-NDP- α -MSH displacement observed at 10 μ M. EC₅₀ = Effective concentration of peptide that was able to generate 50% maximal intracellular cAMP accumulation (N=4). Act % = % of cAMP produced at 10 μ M ligand concentration, in relation to MT-II. The peptides were tested at a range of concentration from 10⁻¹⁰ to 10⁻⁵ nM.